Mesoblast (ASX:MSB) joined the S&P/ASX 200 Index before market open on Thursday, according to a same-day filing with the Australian bourse.
The company, which develops treatment for life-threatening inflammatory conditions, saw shares down almost 4% in recent Thursday trade.